-
1.发明申请PROGNOSTIC MARKERS FOR CLASSIFYING COLORECTAL CARCINOMA ON THE BASIS OF EXPRESSION PROFILES OF BIOLOGICAL SAMPLES 审中-公开基于生物样本表达概况分类的色素标志物的预防标记公开(公告)号：US20090269775A1
公开(公告)日：2009-10-29
申请号：US12519216
申请日：2007-11-01
CPC分类号： C12Q1/6886 , C12Q2600/118 , C12Q2600/158
摘要： The invention relates to the use of gene expression profiles for predicting the probability of recurrence or metastases to develop in remote organs of patients from which a primary colon carcinoma has been removed.
摘要翻译： 本发明涉及使用基因表达谱来预测已经去除原发性结肠癌的患者的远端器官中发生复发或转移的可能性。
-
公开(公告)号：US20110287957A1
公开(公告)日：2011-11-24
申请号：US13111514
申请日：2011-05-19
申请人： Andre Rosenthal , Bernd Hinzmann , Tobias Mayr , Hans-Peter Adams
发明人： Andre Rosenthal , Bernd Hinzmann , Tobias Mayr , Hans-Peter Adams
CPC分类号： C12Q1/6886 , C12Q1/6834 , C12Q2600/158 , C12Q2600/16 , C12Q2600/178
摘要： The invention pertains to a method for early detection and screening of colorectal cancer in human subjects based on RNA isolated from blood obtained from said subject. According to the invention, the expression of at least 3, 5, 8, 30, 60, 102, 202, 55, 1002 or 1002 RNAs listed in Tables 1-15 are measured. Using the invention, an accurate and noninvasive screening and diagnosis tool for colorectal cancer is provided with a sensitivity of at least 80% and a specificity of 85% that has high clinical utility and the potential for broad adoption.
摘要翻译： 本发明涉及一种基于从所述受试者获得的血液中分离的RNA来早期检测和筛选人类受试者的结肠直肠癌的方法。 根据本发明，测量表1-15中列出的至少3,5,8,30,60,102,202,55,1002或1002个RNA的表达。 使用本发明，提供用于结肠直肠癌的精确和无创的筛查和诊断工具，具有至少80％的敏感性和85％的特异性，具有高临床效用和广泛采用的潜力。
-
公开(公告)号：US20130065791A1
公开(公告)日：2013-03-14
申请号：US13698895
申请日：2011-05-19
申请人： André Rosenthal , Bernd Hinzmann , Tobias Mayr , Hans-Peter Adams
发明人： André Rosenthal , Bernd Hinzmann , Tobias Mayr , Hans-Peter Adams
CPC分类号： C12Q1/6886 , C12Q1/6834 , C12Q2600/158 , C12Q2600/16 , C12Q2600/178
摘要： The invention pertains to a method for early detection and screening of colorectal cancer in human subjects based on RNA isolated from blood obtained from said subject. According to the invention, the abundance of at least 3, 5, 8, 30, 60, 102, 202, 55, 1002 or 1002 RNAs listed in tables 1 to 13 is measured. Using the invention, an accurate and noninvasive screening and diagnosis tool for colorectal cancer is provided with a sensitivity of at least 80% and a specificity of 85% that has high clinical utility and the potential for broad adoption.
摘要翻译： 本发明涉及一种基于从所述受试者获得的血液中分离的RNA来早期检测和筛选人类受试者的结肠直肠癌的方法。 根据本发明，测量表1至13中列出的至少3,5,8,30,60,102,202,55,1002或1002个RNA的丰度。 使用本发明，提供用于结肠直肠癌的精确和无创的筛查和诊断工具，具有至少80％的敏感性和85％的特异性，具有高临床效用和广泛采用的潜力。
-
-
搜索结果
3 条记录 (耗时 0.034 秒)
